IBX
IMAGIONBIO FPO [IBX]
Healthcare · ASX Small Cap
$0.0190 +0.0%
Updated 26 Mar 2026 · Scores refresh every scan
⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Score Breakdown
Technical52
Catalyst50
Sentiment50
Fundamental11
Momentum59
Risk Gate37
Get alerts when IBX's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- MACD just crossed bullish — momentum is shifting to the upside
- Stochastic just turned bullish from a low level — early reversal sign
- Volume surging at 2.2x normal while price falls — heavy selling pressure
- Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
- Volatility is expanding fast — choppy price action, so buckle up
- Critical cash runway (1.8 quarters)
- 4C filed 2026-01-28
- Very high P/S ratio (141.1x)
- Revenue in sharp decline (-95%)
- Micro-cap ($5-20M) - high risk
- Sentiment is mixed — no strong consensus either way
- Strong long-term momentum — up 84% over the past year (excluding last month)
- Altman Z-Score distress zone (1.32 < 1.81, low-confidence approx)
- Low-priced stock risk ($0.021)
- RBA hiking (-3pts)
Risk Signals
- Trading below both moving averages — the trend is working against this one
- Below the 200-day average — the long-term trend is still working against it
- Piotroski F-Score weak (3/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Revenue declining at -95% — the top line is shrinking
- The bigger volume days are the down days — volume-weighted momentum is negative (-1.01%/day)
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about IBX
3 free messages/day · Unlimited with Pro
Recent Catalysts
NONE Appendix 4G and Corporate Governance Statement
LOW FY25 Appendix 4E and Annual Report
LOW Appendix 4C and Quarterly Activities Report - December 2025
MEDIUM IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial
Recent ASX Announcements
| 2026-02-27 | Appendix 4G and Corporate Governance Statement |
| 2026-02-27 | FY25 Appendix 4E and Annual Report PRICE SENSITIVE |
| 2026-02-01 | IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial PRICE SENSITIVE |
| 2026-01-28 | Appendix 4C and Quarterly Activities Report - December 2025 PRICE SENSITIVE |
Key Metrics
$10.3M
Market Cap
2.1M
Avg Volume
2.2x
Vol Ratio
$0.01 — $0.06
52-Week Range
N/A
Short Interest
2 qtrs
Cash Runway
N/A
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 70% |
| L | Leader vs Laggard | laggard | RS: -5 |
| I | Institutional Sponsorship | weak | Inst: 0% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #84 of 117 · Sector avg: 46
View all Healthcare signals →Track IBX and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required